| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Neuropathies | 15 | 2025 | 43 | 2.370 |
Why?
|
| Diabetes Mellitus, Experimental | 10 | 2026 | 207 | 1.500 |
Why?
|
| Insulin-Secreting Cells | 9 | 2026 | 453 | 1.110 |
Why?
|
| Neural Conduction | 8 | 2025 | 72 | 0.840 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 2024 | 1 | 0.840 |
Why?
|
| Hypotension, Orthostatic | 1 | 2024 | 3 | 0.840 |
Why?
|
| Autoimmunity | 1 | 2024 | 195 | 0.730 |
Why?
|
| Gastric Inhibitory Polypeptide | 5 | 2026 | 12 | 0.690 |
Why?
|
| Hyperglycemia | 3 | 2015 | 186 | 0.690 |
Why?
|
| Ganglia, Spinal | 6 | 2024 | 75 | 0.620 |
Why?
|
| Insulin | 12 | 2026 | 1225 | 0.620 |
Why?
|
| Vital Statistics | 1 | 2018 | 3 | 0.580 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 811 | 0.550 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2026 | 67 | 0.490 |
Why?
|
| Glucagon-Like Peptides | 3 | 2026 | 24 | 0.450 |
Why?
|
| Mice | 33 | 2026 | 12698 | 0.450 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2026 | 17 | 0.450 |
Why?
|
| Islets of Langerhans | 4 | 2022 | 568 | 0.440 |
Why?
|
| Electroretinography | 3 | 2025 | 82 | 0.430 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2011 | 56 | 0.430 |
Why?
|
| Mice, Inbred C57BL | 17 | 2026 | 3598 | 0.420 |
Why?
|
| Diabetic Retinopathy | 3 | 2025 | 81 | 0.410 |
Why?
|
| Animals | 44 | 2026 | 28894 | 0.400 |
Why?
|
| Diet, High-Fat | 5 | 2026 | 143 | 0.390 |
Why?
|
| Glucagon | 3 | 2022 | 114 | 0.380 |
Why?
|
| Glucose | 5 | 2026 | 704 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2015 | 450 | 0.360 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 373 | 0.360 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 71 | 0.330 |
Why?
|
| Neuronal Outgrowth | 4 | 2024 | 6 | 0.330 |
Why?
|
| Liver Neoplasms | 4 | 2015 | 831 | 0.330 |
Why?
|
| Hepatocytes | 1 | 2011 | 137 | 0.320 |
Why?
|
| Point-of-Care Systems | 2 | 2024 | 155 | 0.320 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 183 | 0.320 |
Why?
|
| Liver | 10 | 2017 | 1231 | 0.310 |
Why?
|
| Quality Control | 1 | 2010 | 130 | 0.300 |
Why?
|
| Antibodies, Antinuclear | 1 | 2010 | 94 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2026 | 1286 | 0.300 |
Why?
|
| Transcription Factors | 4 | 2026 | 1717 | 0.300 |
Why?
|
| Obesity | 3 | 2026 | 1061 | 0.300 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 310 | 0.300 |
Why?
|
| Weight Gain | 3 | 2018 | 134 | 0.290 |
Why?
|
| Calmodulin | 2 | 2007 | 50 | 0.280 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 2024 | 3 | 0.270 |
Why?
|
| Rats | 13 | 2022 | 4071 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2020 | 686 | 0.270 |
Why?
|
| Mice, Knockout | 9 | 2026 | 2207 | 0.260 |
Why?
|
| Proglucagon | 3 | 2022 | 5 | 0.260 |
Why?
|
| Autoantibodies | 3 | 2024 | 286 | 0.260 |
Why?
|
| Stem Cells | 2 | 2020 | 396 | 0.260 |
Why?
|
| Fibroblast Growth Factors | 3 | 2017 | 89 | 0.260 |
Why?
|
| Venoms | 1 | 2007 | 11 | 0.260 |
Why?
|
| Stress, Physiological | 2 | 2026 | 256 | 0.260 |
Why?
|
| Insulin Resistance | 6 | 2026 | 391 | 0.250 |
Why?
|
| Sulfonylurea Receptors | 1 | 2026 | 50 | 0.250 |
Why?
|
| Peptides | 3 | 2022 | 669 | 0.240 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2026 | 81 | 0.240 |
Why?
|
| Neurons | 5 | 2024 | 1619 | 0.240 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2023 | 0.240 |
Why?
|
| Fructose | 1 | 2026 | 38 | 0.230 |
Why?
|
| Hand Strength | 1 | 2026 | 60 | 0.230 |
Why?
|
| Sarcopenia | 1 | 2026 | 22 | 0.230 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 412 | 0.230 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 2 | 2017 | 6 | 0.230 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2026 | 72 | 0.230 |
Why?
|
| Peripheral Nerves | 2 | 2022 | 39 | 0.220 |
Why?
|
| Muscular Atrophy | 1 | 2026 | 49 | 0.220 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 257 | 0.220 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 54 | 0.220 |
Why?
|
| Neuropeptides | 1 | 2005 | 113 | 0.220 |
Why?
|
| Neurotransmitter Agents | 1 | 2005 | 102 | 0.210 |
Why?
|
| Male | 29 | 2026 | 47075 | 0.210 |
Why?
|
| Weight Loss | 1 | 2026 | 245 | 0.210 |
Why?
|
| Frailty | 1 | 2026 | 103 | 0.200 |
Why?
|
| Catecholamines | 1 | 2024 | 94 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2026 | 3620 | 0.200 |
Why?
|
| Circadian Rhythm | 1 | 2026 | 295 | 0.200 |
Why?
|
| Feeding Behavior | 1 | 2026 | 350 | 0.190 |
Why?
|
| Serotonin | 1 | 2024 | 211 | 0.190 |
Why?
|
| Histological Techniques | 1 | 2022 | 33 | 0.190 |
Why?
|
| Apoptosis | 5 | 2021 | 1752 | 0.180 |
Why?
|
| Dopamine | 1 | 2024 | 280 | 0.180 |
Why?
|
| Cell Line | 7 | 2021 | 2483 | 0.180 |
Why?
|
| Culture Media, Conditioned | 2 | 2020 | 102 | 0.180 |
Why?
|
| Diet, High-Protein | 1 | 2022 | 1 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2026 | 1790 | 0.180 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2022 | 28 | 0.180 |
Why?
|
| Docosahexaenoic Acids | 1 | 2022 | 35 | 0.180 |
Why?
|
| Nerve Fibers | 2 | 2019 | 40 | 0.170 |
Why?
|
| Dietary Carbohydrates | 2 | 2018 | 39 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 977 | 0.170 |
Why?
|
| Japan | 2 | 2019 | 303 | 0.170 |
Why?
|
| Electrocardiography | 1 | 2024 | 527 | 0.170 |
Why?
|
| Pyruvaldehyde | 1 | 2021 | 10 | 0.170 |
Why?
|
| Peripheral Nervous System | 1 | 2021 | 21 | 0.170 |
Why?
|
| Tooth, Deciduous | 1 | 2020 | 3 | 0.170 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2020 | 30 | 0.160 |
Why?
|
| Aging | 1 | 2026 | 770 | 0.160 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2020 | 75 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 29 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 129 | 0.160 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2018 | 123 | 0.160 |
Why?
|
| Thermosensing | 1 | 2019 | 4 | 0.150 |
Why?
|
| Arginase | 4 | 2001 | 15 | 0.150 |
Why?
|
| Spiro Compounds | 1 | 2019 | 24 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2022 | 489 | 0.150 |
Why?
|
| Dental Pulp | 1 | 2019 | 5 | 0.150 |
Why?
|
| Calcium Channels, L-Type | 1 | 2019 | 38 | 0.150 |
Why?
|
| Rats, Wistar | 4 | 2019 | 304 | 0.150 |
Why?
|
| Electrodiagnosis | 1 | 2019 | 9 | 0.150 |
Why?
|
| Pyrazines | 1 | 2019 | 98 | 0.150 |
Why?
|
| Humans | 29 | 2026 | 98076 | 0.150 |
Why?
|
| Exocytosis | 1 | 2019 | 109 | 0.140 |
Why?
|
| Retina | 1 | 2020 | 221 | 0.140 |
Why?
|
| Cyclin D2 | 1 | 2018 | 18 | 0.140 |
Why?
|
| Cells, Cultured | 7 | 2024 | 2855 | 0.140 |
Why?
|
| Middle Aged | 13 | 2025 | 29427 | 0.140 |
Why?
|
| Bone Morphogenetic Protein 4 | 2 | 2015 | 16 | 0.140 |
Why?
|
| Blood Glucose | 4 | 2026 | 911 | 0.140 |
Why?
|
| Cell Nucleus | 3 | 2019 | 615 | 0.130 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 194 | 0.130 |
Why?
|
| Diet, Carbohydrate Loading | 1 | 2017 | 2 | 0.130 |
Why?
|
| Organ Specificity | 3 | 2017 | 287 | 0.130 |
Why?
|
| Atherosclerosis | 1 | 2020 | 266 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 278 | 0.130 |
Why?
|
| Dietary Sucrose | 1 | 2017 | 14 | 0.130 |
Why?
|
| Female | 17 | 2026 | 51535 | 0.130 |
Why?
|
| Adenosine Triphosphate | 1 | 2018 | 319 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2018 | 135 | 0.130 |
Why?
|
| Mice, Transgenic | 7 | 2007 | 1604 | 0.130 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2017 | 30 | 0.130 |
Why?
|
| Myoblasts | 1 | 2017 | 34 | 0.130 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 98 | 0.130 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2017 | 57 | 0.120 |
Why?
|
| Energy Metabolism | 3 | 2017 | 315 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 642 | 0.120 |
Why?
|
| Neurites | 3 | 2024 | 38 | 0.120 |
Why?
|
| Receptors, Gastrointestinal Hormone | 3 | 2026 | 10 | 0.120 |
Why?
|
| Autoantigens | 3 | 2002 | 145 | 0.120 |
Why?
|
| Glycolysis | 1 | 2017 | 198 | 0.120 |
Why?
|
| Glucose Tolerance Test | 4 | 2019 | 239 | 0.110 |
Why?
|
| Linagliptin | 2 | 2026 | 3 | 0.110 |
Why?
|
| Clostridium | 1 | 2015 | 25 | 0.110 |
Why?
|
| Glucose Intolerance | 3 | 2026 | 101 | 0.110 |
Why?
|
| Eating | 2 | 2026 | 164 | 0.110 |
Why?
|
| Palmitic Acid | 1 | 2015 | 29 | 0.110 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Tissue Culture Techniques | 2 | 2011 | 81 | 0.110 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2014 | 3 | 0.110 |
Why?
|
| Roseolovirus Infections | 1 | 2014 | 7 | 0.110 |
Why?
|
| Liver Diseases | 4 | 2001 | 249 | 0.110 |
Why?
|
| KATP Channels | 1 | 2014 | 18 | 0.110 |
Why?
|
| Diabetic Foot | 1 | 2014 | 16 | 0.100 |
Why?
|
| Herpesvirus 6, Human | 1 | 2014 | 15 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 412 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2015 | 119 | 0.100 |
Why?
|
| Adipocytes, White | 1 | 2013 | 6 | 0.100 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2013 | 5 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2020 | 2063 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2014 | 64 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1255 | 0.100 |
Why?
|
| Keratinocytes | 1 | 2014 | 156 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 668 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 198 | 0.100 |
Why?
|
| Steroids | 1 | 2014 | 168 | 0.100 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 142 | 0.090 |
Why?
|
| Wound Healing | 2 | 2014 | 384 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 222 | 0.090 |
Why?
|
| Neural Crest | 1 | 2012 | 35 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2012 | 480 | 0.090 |
Why?
|
| Diet | 1 | 2015 | 469 | 0.090 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Calcineurin | 1 | 2011 | 20 | 0.090 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2011 | 30 | 0.090 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 52 | 0.090 |
Why?
|
| Muscle, Skeletal | 3 | 2026 | 521 | 0.090 |
Why?
|
| Response Elements | 1 | 2011 | 68 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1646 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 707 | 0.080 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 65 | 0.080 |
Why?
|
| ROC Curve | 2 | 2025 | 794 | 0.080 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2020 | 39 | 0.080 |
Why?
|
| Calcium Signaling | 1 | 2011 | 142 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 147 | 0.080 |
Why?
|
| Adult | 7 | 2026 | 29538 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 3021 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1133 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2010 | 39 | 0.080 |
Why?
|
| Protein Transport | 1 | 2011 | 448 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2015 | 730 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2026 | 2572 | 0.080 |
Why?
|
| Cytodiagnosis | 3 | 1985 | 48 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 643 | 0.070 |
Why?
|
| Cell Survival | 3 | 2021 | 1014 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2002 | 502 | 0.070 |
Why?
|
| Aged | 7 | 2025 | 21758 | 0.070 |
Why?
|
| Biomarkers | 4 | 2013 | 2020 | 0.070 |
Why?
|
| Creatine Kinase | 2 | 1998 | 51 | 0.070 |
Why?
|
| Receptors, Glucagon | 2 | 2020 | 11 | 0.060 |
Why?
|
| Transcription Factor CHOP | 1 | 2007 | 16 | 0.060 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2026 | 35 | 0.060 |
Why?
|
| Molecular Chaperones | 1 | 2007 | 125 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2007 | 178 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2026 | 30 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2026 | 51 | 0.060 |
Why?
|
| Age of Onset | 1 | 2026 | 367 | 0.060 |
Why?
|
| Cyclic AMP | 2 | 2019 | 277 | 0.060 |
Why?
|
| Streptozocin | 2 | 2016 | 57 | 0.060 |
Why?
|
| Mice, Inbred ICR | 1 | 2005 | 76 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 750 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 889 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2025 | 141 | 0.060 |
Why?
|
| Benzoates | 1 | 2005 | 33 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2005 | 23 | 0.060 |
Why?
|
| United States | 1 | 2018 | 8196 | 0.060 |
Why?
|
| Valine | 1 | 2005 | 48 | 0.050 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 40 | 0.050 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 46 | 0.050 |
Why?
|
| Sitagliptin Phosphate | 1 | 2024 | 3 | 0.050 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2024 | 7 | 0.050 |
Why?
|
| Neuropeptide Y | 1 | 2024 | 29 | 0.050 |
Why?
|
| Body Weight | 1 | 2026 | 455 | 0.050 |
Why?
|
| Chemokine CXCL12 | 1 | 2024 | 38 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2013 | 0.050 |
Why?
|
| Pedigree | 1 | 2026 | 980 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2026 | 674 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2005 | 118 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2026 | 557 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2026 | 721 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2783 | 0.050 |
Why?
|
| Pyridines | 1 | 2026 | 318 | 0.050 |
Why?
|
| Memory | 1 | 2026 | 234 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 993 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2026 | 413 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2024 | 207 | 0.050 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2022 | 1 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2002 | 24 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 68 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2022 | 137 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2022 | 36 | 0.050 |
Why?
|
| Pancreatic Hormones | 1 | 2022 | 17 | 0.050 |
Why?
|
| Rats, Inbred F344 | 1 | 2022 | 161 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2001 | 1235 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2022 | 113 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 72 | 0.040 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2020 | 3 | 0.040 |
Why?
|
| Cell Death | 1 | 2022 | 257 | 0.040 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Fovea Centralis | 1 | 2020 | 19 | 0.040 |
Why?
|
| Tooth Exfoliation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Expression | 1 | 2005 | 1320 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2002 | 205 | 0.040 |
Why?
|
| Ankle Brachial Index | 1 | 2020 | 29 | 0.040 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2021 | 119 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2020 | 22 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 200 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2020 | 73 | 0.040 |
Why?
|
| Autophagy | 1 | 2022 | 177 | 0.040 |
Why?
|
| Aldehyde Reductase | 1 | 2019 | 9 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2001 | 263 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2020 | 132 | 0.040 |
Why?
|
| Electromyography | 1 | 2020 | 233 | 0.040 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 1999 | 5 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 446 | 0.040 |
Why?
|
| Sensory Receptor Cells | 1 | 2019 | 40 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 7389 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1782 | 0.040 |
Why?
|
| Epidermis | 1 | 2019 | 106 | 0.040 |
Why?
|
| Calcitonin | 1 | 2019 | 41 | 0.040 |
Why?
|
| Phosphocreatine | 1 | 1998 | 15 | 0.040 |
Why?
|
| Cell Movement | 2 | 2020 | 814 | 0.040 |
Why?
|
| Substance P | 1 | 2019 | 62 | 0.040 |
Why?
|
| Motor Skills | 1 | 2019 | 80 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2002 | 386 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 778 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 227 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 822 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2019 | 381 | 0.030 |
Why?
|
| Pregnancy | 1 | 2026 | 3244 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2019 | 155 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 94 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 945 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 720 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 525 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2019 | 154 | 0.030 |
Why?
|
| Starch | 1 | 2017 | 9 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 19 | 0.030 |
Why?
|
| Antioxidants | 1 | 2019 | 236 | 0.030 |
Why?
|
| Uncoupling Protein 1 | 1 | 2017 | 45 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2002 | 552 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2017 | 30 | 0.030 |
Why?
|
| Graft Survival | 1 | 2001 | 994 | 0.030 |
Why?
|
| Hexokinase | 1 | 2017 | 23 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2017 | 83 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 1996 | 31 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 650 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 62 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2020 | 601 | 0.030 |
Why?
|
| Endotoxins | 1 | 1996 | 36 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 88 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 1999 | 324 | 0.030 |
Why?
|
| Erythrocytes | 2 | 2001 | 242 | 0.030 |
Why?
|
| Transcription Factor Pit-1 | 1 | 2015 | 5 | 0.030 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2015 | 24 | 0.030 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2015 | 14 | 0.030 |
Why?
|
| Ectoderm | 1 | 2015 | 31 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2015 | 50 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2002 | 1110 | 0.030 |
Why?
|
| Rats, Zucker | 1 | 2015 | 38 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 4025 | 0.030 |
Why?
|
| Hepatectomy | 1 | 1996 | 203 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2001 | 1186 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1995 | 0.030 |
Why?
|
| Phlorhizin | 1 | 2014 | 3 | 0.030 |
Why?
|
| Diazoxide | 1 | 2014 | 19 | 0.030 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 1994 | 5 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2015 | 131 | 0.030 |
Why?
|
| Lung Diseases | 1 | 1996 | 284 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1994 | 57 | 0.030 |
Why?
|
| Growth Substances | 1 | 1994 | 79 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 73 | 0.030 |
Why?
|
| Foot | 1 | 2014 | 64 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 139 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2013 | 21 | 0.020 |
Why?
|
| Adipokines | 1 | 2013 | 20 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 37 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2013 | 32 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 2013 | 53 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2013 | 153 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 4116 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 64 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 175 | 0.020 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2012 | 6 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 178 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2012 | 31 | 0.020 |
Why?
|
| Nerve Growth Factor | 1 | 2012 | 19 | 0.020 |
Why?
|
| Incretins | 1 | 2012 | 15 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2012 | 37 | 0.020 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2012 | 30 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 161 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 174 | 0.020 |
Why?
|
| Ovalbumin | 2 | 2002 | 105 | 0.020 |
Why?
|
| Mass Screening | 2 | 1989 | 745 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 566 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 353 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1255 | 0.020 |
Why?
|
| Child | 2 | 2020 | 7681 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2011 | 55 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 2011 | 118 | 0.020 |
Why?
|
| Intestines | 1 | 1994 | 441 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 332 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 400 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 591 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 720 | 0.020 |
Why?
|
| Immunization, Secondary | 2 | 2002 | 42 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 10972 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1285 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 1991 | 122 | 0.020 |
Why?
|
| Homeostasis | 1 | 2012 | 474 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1815 | 0.020 |
Why?
|
| Quality of Life | 1 | 1996 | 1895 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 689 | 0.020 |
Why?
|
| Reference Values | 2 | 2001 | 608 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1989 | 323 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 2 | 1985 | 218 | 0.010 |
Why?
|
| Oxygen Consumption | 2 | 1996 | 239 | 0.010 |
Why?
|
| Valsartan | 1 | 2005 | 10 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 2005 | 63 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 98 | 0.010 |
Why?
|
| Probability | 1 | 1985 | 356 | 0.010 |
Why?
|
| Colonic Neoplasms | 2 | 2001 | 582 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1989 | 1105 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1989 | 1302 | 0.010 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2002 | 18 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2002 | 32 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 141 | 0.010 |
Why?
|
| Convalescence | 1 | 2001 | 10 | 0.010 |
Why?
|
| Hepatitis | 1 | 2001 | 32 | 0.010 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2001 | 3 | 0.010 |
Why?
|
| Calibration | 1 | 2001 | 110 | 0.010 |
Why?
|
| Cholangiocarcinoma | 1 | 2001 | 83 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 910 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2001 | 68 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2002 | 234 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 9711 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2002 | 291 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 780 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2001 | 148 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 860 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 480 | 0.010 |
Why?
|
| Self Tolerance | 1 | 1999 | 26 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 165 | 0.010 |
Why?
|
| Galactosamine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Transgenes | 1 | 1999 | 173 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 1999 | 174 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1998 | 74 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1998 | 74 | 0.010 |
Why?
|
| Neoplasms | 3 | 1985 | 3334 | 0.010 |
Why?
|
| Lupus Nephritis | 1 | 1999 | 85 | 0.010 |
Why?
|
| Rabbits | 1 | 1999 | 581 | 0.010 |
Why?
|
| Necrosis | 1 | 1998 | 212 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1998 | 272 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1998 | 313 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1945 | 0.010 |
Why?
|
| Sulfur Dioxide | 1 | 1996 | 1 | 0.010 |
Why?
|
| Mitochondria, Liver | 1 | 1996 | 29 | 0.010 |
Why?
|
| Hepatic Veins | 1 | 1996 | 27 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1996 | 59 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1996 | 61 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 1996 | 61 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1996 | 57 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 1996 | 72 | 0.010 |
Why?
|
| Portal Vein | 1 | 1996 | 121 | 0.010 |
Why?
|
| Monitoring, Intraoperative | 1 | 1996 | 115 | 0.010 |
Why?
|
| Syndrome | 1 | 1996 | 438 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1416 | 0.010 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 1994 | 7 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 1994 | 10 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1994 | 239 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 1476 | 0.010 |
Why?
|
| Sepsis | 1 | 1998 | 427 | 0.010 |
Why?
|
| Gallbladder Neoplasms | 1 | 1993 | 24 | 0.010 |
Why?
|
| Epithelium | 1 | 1994 | 316 | 0.010 |
Why?
|
| Hemolysis | 1 | 1993 | 66 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 1028 | 0.010 |
Why?
|
| Cytokines | 1 | 1996 | 889 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 1327 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 2041 | 0.010 |
Why?
|
| Adolescent | 2 | 1996 | 10079 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1994 | 356 | 0.010 |
Why?
|
| Computers | 2 | 1982 | 102 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1991 | 280 | 0.010 |
Why?
|
| Chickens | 1 | 1991 | 195 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1991 | 290 | 0.010 |
Why?
|
| Calpain | 1 | 1991 | 113 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1994 | 709 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 1535 | 0.000 |
Why?
|
| Brain | 1 | 1998 | 2430 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 2666 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 3605 | 0.000 |
Why?
|